hypoglycemia semaglutide Can Type 1 and Type 2 Diabetes Patients Use GLP-1 Medications Indications for oral semaglutide |

11.6 Evidence-Based Position Based on current literature: GLP-1 receptor agonists do not inherently cause universal nutrient depletion Intake-related vulnerability is plausible and patient-dependent Long-term micronutrient data remain limited Risk increases with magnitude and duration of weight loss Structured dietary strategy is protective Weight loss pharmacotherapy should be paired with nutritional planning

However, it should be used alongside lifestyle interventions

The table below shows the GLP-1 agonists currently available in the U.S

say they are taking GLP-1 drugs for weight loss, according to a 2024 poll conducted by the San Francisco-based health policy nonprofit KFF

Many health insurance plans don't cover the weight loss drug Zepbound because it's so new